Abdulrahman Al Raizah: Mitapivat for Transfusion-Dependent Thalassemia – The ENERGIZE-T Phase 3 Trial
Abdulrahman Al Raizah, Mortality and Morbidity Meeting Lead, Adult Hematology Division at Ministry of National Guard Health Affairs (MNGHA), shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in The Lancet, adding:
“Just published in The Lancet, the ENERGIZE-T Phase 3 trial evaluated mitapivat in transfusion-dependent alpha and beta-thalassaemia, showing significant reductions in transfusion burden and cases of transfusion independence.
Following last year’s published ENERGIZE Phase 3 trial in non-transfusion-dependent thalassaemia, this second milestone underscores the clinical potential of oral pyruvate kinase activators across the full spectrum of thalassaemia management.
Participating in both the ENERGIZE trial last year and the ENERGIZE-T trial this year reflects the driving role of Ministry of National Guard Health Affairs (MNGHA) and King Abdullah International Medical Research Center (KAIMRC) in advancing global clinical research in hemoglobinopathies.
Sincere thanks to Prof Ahmed Alaskar and the entire KAIMRC team for their support—and above all, to the patients whose trust makes this work possible.
Privileged to have served as the site Principal Investigator for both trials.”
Title: Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Authors: Maria Domenica Cappellini, Sujit Sheth, Ali Taher, Hanny Al-Samkari, Ali Bülent Antmen, David Beneitez, Giovanna Cannas, Thomas Coates, Lauren Czapla, Jayme L Dahlin, Jeremie H Estepp, Elizabeth Feenstra, Pencho Georgiev, Sarah Gheuens, Gavrielle M Price, Andreas Glenthøj, Khaled M Musallam, Kareem Osman, John B Porter, Hui Shao, Katrin Uhlig, Eduard J van Beers, Vip Viprakasit, Kevin H M Kuo, Antonis Kattamis
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 12, 2026, 17:55Dries De Wolf: Honored to Have Wolfgang Miesbach Comment on Our Latest Research
-
Sep 12, 2026, 17:53Usman Waheed: Introducing the Discovery of the 49th ISBT Blood Group System
-
Sep 12, 2026, 17:51Maria Sabater Lleal: Happy to Share Our Latest Work Exploring the Genetic Determinants of PE in VTE
-
Sep 12, 2026, 17:51Jeff Sternlicht: Why LDL-C and ApoB Remain King of the Hill?
-
Sep 12, 2026, 17:49Kalyan Roy: TRAGS – An Emerging Transfusion Safety Concern
-
Sep 12, 2026, 17:48Jason Fung: What Happened to “Statins Save Lives”?
-
Sep 12, 2026, 17:47Eric Topol: Most Supplements and Vitamins Offer Little Proven Benefit
-
Sep 12, 2026, 17:44Manuel Monreal: Clinical Characteristics, Treatment, and Outcomes in Hispanic vs Caucasian Patients With VTE
-
Sep 12, 2026, 17:43Sidi Mohamed El Amine Benlazar: CPX-351 and Ruxolitinib in Advanced-Phase Myeloproliferative Neoplasms